Vera Therapeutics (VERA) Invested Capital (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Invested Capital data on file, last reported at $574.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 1.91% year-over-year to $574.7 million; the trailing twelve-month figure through Mar 2026 stood at $574.7 million (down 1.91% YoY), and the FY2025 full-year result was $679.4 million, up 8.21% from the prior year.
• Invested Capital for Q1 2026 stood at $574.7 million, down from $679.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $679.4 million in Q4 2025 and bottomed at $101.7 million in Q4 2022.
• The 5-year median for Invested Capital is $339.5 million (2024), against an average of $337.2 million.
• The widest annual swing landed in 2024, when Invested Capital surged 314.25%; it then slipped 1.91% in 2026.
• A 5-year view of Invested Capital shows it stood at $101.7 million in 2022, then soared by 49.0% to $151.6 million in 2023, then soared by 314.25% to $627.8 million in 2024, then rose by 8.21% to $679.4 million in 2025, then declined by 15.4% to $574.7 million in 2026.
• The last three Invested Capital figures came in at $574.7 million (Q1 2026), $679.4 million (Q4 2025), and $473.5 million (Q3 2025), per Business Quant data.

Peer Comparison